{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T12:24:35Z","timestamp":1782563075600,"version":"3.54.5"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T00:00:00Z","timestamp":1755129600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100030905","name":"Suomen Parkinson-s\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030905","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005609","name":"Turun Yliopisto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005609","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004212","name":"P\u00e4ivikki ja Sakari Sohlbergin S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004212","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009094","name":"Turun Yliopistollisen Keskussairaalan Koulutus- ja Tutkimuss\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009094","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003125","name":"Suomen Kulttuurirahasto","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003125","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["npj Parkinsons Dis."],"DOI":"10.1038\/s41531-025-01116-7","type":"journal-article","created":{"date-parts":[[2025,8,14]],"date-time":"2025-08-14T20:36:29Z","timestamp":1755203789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Increased frontal [123I]FP-CIT binding in Parkinson\u2019s disease patients with self-reported REM sleep behavior disorder"],"prefix":"10.1038","volume":"11","author":[{"given":"Elina","family":"Jaakkola","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jani","family":"Ijas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juho","family":"Joutsa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tero","family":"Vahlberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elina","family":"Myller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikael","family":"Eklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simo","family":"Nuuttila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirsi","family":"Murtom\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuomas","family":"Mertsalmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reeta","family":"Levo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommi","family":"Noponen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toni","family":"Ihalainen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Scheperjans","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valtteri","family":"Kaasinen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,14]]},"reference":[{"key":"1116_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/j.1749-6632.2009.05115.x","volume":"1184","author":"BF Boeve","year":"2010","unstructured":"Boeve, B. F. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. Ann. N. Y Acad. Sci. 1184, 15\u201354 (2010).","journal-title":"Ann. N. Y Acad. Sci."},{"key":"1116_CR2","doi-asserted-by":"publisher","first-page":"681","DOI":"10.3233\/JPD-150685","volume":"5","author":"P Mahlknecht","year":"2015","unstructured":"Mahlknecht, P., Seppi, K. & Poewe, W. The concept of prodromal Parkinson\u2019s disease. J. Parkinsons Dis. 5, 681\u2013697 (2015).","journal-title":"J. Parkinsons Dis."},{"key":"1116_CR3","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/S1474-4422(11)70152-1","volume":"10","author":"A Iranzo","year":"2011","unstructured":"Iranzo, A. et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 10, 797\u2013805 (2011).","journal-title":"Lancet Neurol."},{"key":"1116_CR4","first-page":"1155","volume":"123","author":"I Eisensehr","year":"2000","unstructured":"Eisensehr, I. et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. Comparison Parkinson\u2019s Dis. Controls Brain 123, 1155\u20131160 (2000).","journal-title":"Comparison Parkinson\u2019s Dis. Controls Brain"},{"key":"1116_CR5","doi-asserted-by":"publisher","first-page":"3300","DOI":"10.1016\/j.neurobiolaging.2015.08.025","volume":"36","author":"D Arnaldi","year":"2015","unstructured":"Arnaldi, D. et al. Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder?. Neurobiol. Aging 36, 3300\u20133305 (2015).","journal-title":"Neurobiol. Aging"},{"key":"1116_CR6","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1111\/ene.13388","volume":"24","author":"SJ Chung","year":"2017","unstructured":"Chung, S. J., Lee, Y., Lee, J. J., Lee, P. H. & Sohn, Y. H. Rapid eye movement sleep behaviour disorder and striatal dopamine depletion in patients with Parkinson\u2019s disease. Eur. J. Neurol. 24, 1314\u20131319 (2017).","journal-title":"Eur. J. Neurol."},{"key":"1116_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s00415-024-12799-y","volume":"272","author":"CE Cicero","year":"2024","unstructured":"Cicero, C. E. et al. Exploring the relation between REM sleep behavior disorder onset and striatal dopaminergic dysfunction in Parkinson\u2019s Disease. J. Neurol. 272, 75 (2024).","journal-title":"J. Neurol."},{"key":"1116_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s13041-021-00875-7","volume":"14","author":"M Valli","year":"2021","unstructured":"Valli, M. et al. VMAT2 availability in Parkinson\u2019s disease with probable REM sleep behaviour disorder. Mol. Brain 14, 165 (2021).","journal-title":"Mol. Brain"},{"key":"1116_CR9","doi-asserted-by":"publisher","first-page":"e894","DOI":"10.1212\/WNL.0000000000006134","volume":"91","author":"G Pagano","year":"2018","unstructured":"Pagano, G. et al. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. Neurology 91, e894\u2013e905 (2018).","journal-title":"Neurology"},{"key":"1116_CR10","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.parkreldis.2020.09.032","volume":"80","author":"YE Kim","year":"2020","unstructured":"Kim, Y. E., Kim, Y. J., Hwang, H. S. & Ma, H. I. REM sleep behavior disorder in early Parkinson\u2019s disease predicts the rapid dopaminergic denervation. Parkinsonism Relat. Disord. 80, 120\u2013126 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1116_CR11","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1016\/j.tins.2013.06.003","volume":"36","author":"L Brichta","year":"2013","unstructured":"Brichta, L., Greengard, P. & Flajolet, M. Advances in the pharmacological treatment of Parkinson\u2019s disease: targeting neurotransmitter systems. Trends Neurosci. 36, 543\u2013554 (2013).","journal-title":"Trends Neurosci."},{"key":"1116_CR12","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1053\/smrv.2001.0174","volume":"6","author":"R Ursin","year":"2002","unstructured":"Ursin, R. Serotonin and sleep. Sleep. Med. Rev. 6, 55\u201369 (2002).","journal-title":"Sleep. Med. Rev."},{"key":"1116_CR13","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.sleep.2007.11.019","volume":"10","author":"PT Teman","year":"2009","unstructured":"Teman, P. T., Tippmann-Peikert, M., Silber, M. H., Slocumb, N. L. & Auger, R. R. Idiopathic rapid-eye-movement sleep disorder: associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. Sleep. Med. 10, 60\u201365 (2009).","journal-title":"Sleep. Med."},{"key":"1116_CR14","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1007\/s11325-021-02417-w","volume":"26","author":"M Meloni","year":"2022","unstructured":"Meloni, M. et al. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson\u2019s disease. Sleep. Breath. 26, 1023\u20131031 (2022).","journal-title":"Sleep. Breath."},{"key":"1116_CR15","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1002\/ana.22691","volume":"71","author":"V Kotagal","year":"2012","unstructured":"Kotagal, V. et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. Ann. Neurol. 71, 560\u2013568 (2012).","journal-title":"Ann. Neurol."},{"key":"1116_CR16","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.5665\/sleep.5000","volume":"38","author":"D Arnaldi","year":"2015","unstructured":"Arnaldi, D. et al. The role of the serotonergic system in REM sleep behavior disorder. Sleep 38, 1505\u20131509 (2015).","journal-title":"Sleep"},{"key":"1116_CR17","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1016\/j.nicl.2018.03.001","volume":"18","author":"H Wilson","year":"2018","unstructured":"Wilson, H., Giordano, B., Turkheimer, F. E., Chaudhuri, K. R. & Politis, M. Serotonergic dysregulation is linked to sleep problems in Parkinson\u2019s disease. Neuroimage Clin. 18, 630\u2013637 (2018).","journal-title":"Neuroimage Clin."},{"key":"1116_CR18","doi-asserted-by":"publisher","first-page":"1087","DOI":"10.2967\/jnumed.111.102277","volume":"53","author":"KE Koopman","year":"2012","unstructured":"Koopman, K. E., la Fleur, S. E., Fliers, E., Serlie, M. J. & Booij, J. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. J. Nucl. Med. 53, 1087\u20131090 (2012).","journal-title":"J. Nucl. Med."},{"key":"1116_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.31083\/j.jin2201018","volume":"22","author":"IH Kwak","year":"2023","unstructured":"Kwak, I. H. et al. Striatal subregion analysis associated with rem sleep behavior disorder in Parkinson\u2019s Disease. J. Integr. Neurosci. 22, 18 (2023).","journal-title":"J. Integr. Neurosci."},{"key":"1116_CR20","doi-asserted-by":"publisher","first-page":"349","DOI":"10.3389\/fnins.2020.00349","volume":"14","author":"R Cao","year":"2020","unstructured":"Cao, R., Chen, X., Xie, C., Hu, P. & Wang, K. Serial dopamine transporter imaging of nigrostriatal function in Parkinson\u2019s disease with probable REM sleep behavior disorder. Front. Neurosci. 14, 349 (2020).","journal-title":"Front. Neurosci."},{"key":"1116_CR21","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.parkreldis.2020.02.001","volume":"72","author":"R Liu","year":"2020","unstructured":"Liu, R., Umbach, D. M., Tr\u00f6ster, A. I., Huang, X. & Chen, H. Non-motor symptoms and striatal dopamine transporter binding in early Parkinson\u2019s disease. Parkinsonism Relat. Disord. 72, 23\u201330 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1116_CR22","first-page":"1129","volume":"37","author":"A Abi-Dargham","year":"1996","unstructured":"Abi-Dargham, A. et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J. Nucl. Med. 37, 1129\u20131133 (1996).","journal-title":"J. Nucl. Med."},{"key":"1116_CR23","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.parkreldis.2020.07.008","volume":"78","author":"N Nicastro","year":"2020","unstructured":"Nicastro, N., Fleury, V., Broc, N., Burkhard, P. R. & Garibotto, V. Extrastriatal 123I-FP-CIT SPECT impairment in degenerative Parkinsonisms. Parkinsonism Relat. Disord. 78, 38\u201343 (2020).","journal-title":"Parkinsonism Relat. Disord."},{"key":"1116_CR24","doi-asserted-by":"publisher","first-page":"102062","DOI":"10.1016\/j.nicl.2019.102062","volume":"25","author":"JJ van der Zande","year":"2020","unstructured":"van der Zande, J. J. et al. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer\u2019s disease pathology: An 123I-FP-CIT SPECT study. Neuroimage Clin. 25, 102062 (2020).","journal-title":"Neuroimage Clin."},{"key":"1116_CR25","first-page":"359","volume":"48","author":"J Booij","year":"2007","unstructured":"Booij, J. et al. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J. Nucl. Med. 48, 359\u2013366 (2007).","journal-title":"J. Nucl. Med."},{"key":"1116_CR26","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.1007\/s00259-019-04324-5","volume":"46","author":"A Pilotto","year":"2019","unstructured":"Pilotto, A. et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson\u2019s disease and in dementia with Lewy bodies: a. Eur. J. Nucl. Med. Mol. Imaging 46, 1642\u20131651 (2019).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1116_CR27","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0969-8051(97)00081-4","volume":"24","author":"I G\u00fcnther","year":"1997","unstructured":"G\u00fcnther, I. et al. [125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. Nucl. Med. Biol. 24, 629\u2013634 (1997).","journal-title":"Nucl. Med. Biol."},{"key":"1116_CR28","doi-asserted-by":"publisher","first-page":"S281","DOI":"10.3233\/JPD-191721","volume":"9","author":"P Borghammer","year":"2019","unstructured":"Borghammer, P. & Van Den Berge, N. Brain-first versus gut-first Parkinson\u2019s disease: a hypothesis. J. Parkinsons Dis. 9, S281\u2013S295 (2019).","journal-title":"J. Parkinsons Dis."},{"key":"1116_CR29","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.2967\/jnumed.110.078337","volume":"51","author":"M Ziebell","year":"2010","unstructured":"Ziebell, M. et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. J. Nucl. Med. 51, 1885\u20131891 (2010).","journal-title":"J. Nucl. Med."},{"key":"1116_CR30","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/ana.24859","volume":"81","author":"G Pagano","year":"2017","unstructured":"Pagano, G., Niccolini, F., Fusar-Poli, P. & Politis, M. Serotonin transporter in Parkinson\u2019s disease: a meta-analysis of positron emission tomography studies. Ann. Neurol. 81, 171\u2013180 (2017).","journal-title":"Ann. Neurol."},{"key":"1116_CR31","doi-asserted-by":"publisher","unstructured":"Garwood, M., Vijayakumar, P., Bohnen, N. I., Koeppe, R. A. & Kotagal, V. Serotonin transporter density in isolated rapid eye movement sleep behavioral disorder. Front. Sleep 2. https:\/\/doi.org\/10.3389\/frsle.2023.1298854 (2024).","DOI":"10.3389\/frsle.2023.1298854"},{"key":"1116_CR32","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.smrv.2010.11.003","volume":"15","author":"JM Monti","year":"2011","unstructured":"Monti, J. M. Serotonin control of sleep-wake behavior. Sleep. Med. Rev. 15, 269\u2013281 (2011).","journal-title":"Sleep. Med. Rev."},{"key":"1116_CR33","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1002\/mds.25037","volume":"27","author":"RB Postuma","year":"2012","unstructured":"Postuma, R. B. et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov. Disord. 27, 913\u2013916 (2012).","journal-title":"Mov. Disord."},{"key":"1116_CR34","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jns.2019.07.025","volume":"404","author":"E Jaakkola","year":"2019","unstructured":"Jaakkola, E. et al. Burden of non-motor symptoms in unclear Parkinsonism and tremor: a study with. J. Neurol. Sci. 404, 124\u2013127 (2019).","journal-title":"J. Neurol. Sci."},{"key":"1116_CR35","doi-asserted-by":"publisher","first-page":"e3097","DOI":"10.1002\/brb3.3097","volume":"13","author":"K Murtom\u00e4ki","year":"2023","unstructured":"Murtom\u00e4ki, K. et al. Dopamine transporter binding in the brain is linked to irritable bowel syndrome in Parkinson\u2019s disease. Brain Behav. 13, e3097 (2023).","journal-title":"Brain Behav."},{"key":"1116_CR36","doi-asserted-by":"publisher","first-page":"895","DOI":"10.1007\/s00702-022-02517-1","volume":"129","author":"M Eklund","year":"2022","unstructured":"Eklund, M. et al. Diagnostic value of micrographia in Parkinson\u2019s disease: a study with. J. Neural Transm.129, 895\u2013904 (2022).","journal-title":"J. Neural Transm."},{"key":"1116_CR37","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1002\/mds.28986","volume":"37","author":"K Murtom\u00e4ki","year":"2022","unstructured":"Murtom\u00e4ki, K. et al. Gastrointestinal symptoms and dopamine transporter asymmetry in early Parkinson\u2019s disease. Mov. Disord. 37, 1284\u20131289 (2022).","journal-title":"Mov. Disord."},{"key":"1116_CR38","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1002\/mds.22340","volume":"23","author":"CG Goetz","year":"2008","unstructured":"Goetz, C. G. et al. Movement disorder society-sponsored revision of the unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov. Disord. 23, 2129\u20132170 (2008).","journal-title":"Mov. Disord."},{"key":"1116_CR39","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/0022-3956(75)90026-6","volume":"12","author":"MF Folstein","year":"1975","unstructured":"Folstein, M. F., Folstein, S. E. & McHugh, P. R. \u201cMini-mental state\u201d. A practical method for grading the cognitive state of patients for the clinician. J. Psychiatr. Res. 12, 189\u2013198 (1975).","journal-title":"J. Psychiatr. Res."},{"key":"1116_CR40","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/archpsyc.1961.01710120031004","volume":"4","author":"AT Beck","year":"1961","unstructured":"Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. & Erbaugh, J. An inventory for measuring depression. Arch. Gen. Psychiatry 4, 561\u2013571 (1961).","journal-title":"Arch. Gen. Psychiatry"},{"key":"1116_CR41","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1002\/mds.21596","volume":"22","author":"KR Chaudhuri","year":"2007","unstructured":"Chaudhuri, K. R. et al. The metric properties of a novel non-motor symptoms scale for Parkinson\u2019s disease: results from an international pilot study. Mov. Disord. 22, 1901\u20131911 (2007).","journal-title":"Mov. Disord."},{"key":"1116_CR42","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1007\/s00259-011-1801-5","volume":"38","author":"L Tossici-Bolt","year":"2011","unstructured":"Tossici-Bolt, L. et al. Calibration of gamma camera systems for a multicentre European 123I-FP-CIT SPECT normal database. Eur. J. Nucl. Med. Mol. Imaging 38, 1529\u20131540 (2011).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1116_CR43","unstructured":"Instructions for use hybrid recon. Stockholm, Sweden: Hermes Medical Solutions (2024)."},{"key":"1116_CR44","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00259-009-1267-x","volume":"37","author":"J Darcourt","year":"2010","unstructured":"Darcourt, J. et al. EANM procedure guidelines for brain neurotransmission SPECT using (123)I-labelled dopamine transporter ligands, version 2. Eur. J. Nucl. Med. Mol. Imaging 37, 443\u2013450 (2010).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1116_CR45","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1016\/j.neurobiolaging.2015.01.016","volume":"36","author":"V Kaasinen","year":"2015","unstructured":"Kaasinen, V., Joutsa, J., Noponen, T., Johansson, J. & Sepp\u00e4nen, M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson\u2019s disease. Neurobiol. Aging 36, 1757\u20131763 (2015).","journal-title":"Neurobiol. Aging"}],"container-title":["npj Parkinson's Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01116-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01116-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01116-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:36:34Z","timestamp":1757392594000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41531-025-01116-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,14]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1116"],"URL":"https:\/\/doi.org\/10.1038\/s41531-025-01116-7","relation":{},"ISSN":["2373-8057"],"issn-type":[{"value":"2373-8057","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,14]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"E.J. reports grants from the Finnish Medical Foundation and the Finnish Parkinson Foundation. J.J. reports research grants from the Sakari Sohlberg\u2019s Foundation, Finnish Research Council, Finnish Medical Foundation, Sigrid Juselius Foundation, Finnish Foundation for Alcohol Studies, University of Turku and Turku University Hospital; conference travel support from Insightec, AbbVie, and Abbott; consulting for Teva Finland, Summaryx, and Adamant Health; lecturer honoraria from Addiktum, Nordic Infucare, Lundbeck, and Novartis; acting as an advisory board member for Teva Finland; and stock ownership of Neurologic Finland and Suomen Neurolaboratorio. ME has received grants from The Finnish Parkinson Foundation, The Finnish Medical Foundation, Maire Taponen Foundation, The Finnish Brain Foundation, Orion Research Foundation and Turku University Hospital (VTR, internal research funding). KM reports grants from Maire Taponen Foundation, the Hospital District of Helsinki and Uusimaa and the Finnish Parkinson Foundation. TN reports lecturer honoraria (GE Healthcare) and research grants (GE Healthcare and Turku University Hospital). FS reports consultancies (Abbvie, Axial Biotherapeutics, Orion Pharma, Teva, Adamant Health), honoraria (Abbvie, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, Biocodex, Biogen), grants (Emil Aaltonen Foundation, Konung Gustav V:s och Drottning Victorias Stiftelse, Olvi Foundation, Yrj\u00f6 Jahnsson Foundation, Stockmann Foundation, Sigrid Juselius Foundation, Research Council of Finland, Hospital District of Helsinki and Uusimaa, Renishaw, Orion Pharma, Abbvie), travel expenses (Lundbeck, NordicInfucare), stock (NeuroInnovation Oy, NeuroBiome Oy, Axial Biotherapeutics). V.K. reports advisory boards (Abbvie, Nordic Infucare AB), honoraria (Orion Pharma, Nordic Infucare AB, Abbvie, Eisai, Lundbeck, Teva, Bial), travel expenses (Nordic Infucar AB), grants (the P\u00e4ivikki and Sakari Sohlberg Foundation, the Finnish Cultural Foundation, the Finnish Parkinson Foundation, the Turku University Foundation, Turku University Hospital (VTR-funds).","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"243"}}